YUNGJIN PHARM's Annual Corporate Group Disclosure – Financial Structure and Largest Shareholder Stake at 52.45%

Total assets 262.4B KRW, total liabilities 170.9B KRW, equity 91.5B KRW, debt ratio 186.9%
Revenue 254.3B KRW, operating profit 3.4B KRW, net loss 0.2B KRW, profitability weakened
Largest shareholder KT&G holds 95,928,655 common shares (52.45%), minority shareholders 47.55%
Securities transaction with affiliate KT&G: acquisition of convertible bonds issued by Yungjin Pharm worth 5.1B KRW
Small-scale goods/services transaction with affiliates: 188M KRW; lease liabilities: 97M KRW
All three outside directors newly appointed in 2026, audit committee formed
Electronic voting system adopted but general shareholder voting rate only 0.13%
[AI Summary]This is a routine mandatory disclosure with no significant positive or negative catalysts, but the high debt ratio, net loss, and low shareholder participation warrant caution regarding financial stability.

Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]
Company: YUNGJIN PHARM (003520)
Submission: YUNGJIN PHARM. CO., LTD
Receipt: 06-01-2026
Under Fair Trade Commission (KFTC)